Stroke COunseling for Risk REduction (SCORRE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03076125 |
Recruitment Status :
Completed
First Posted : March 10, 2017
Last Update Posted : December 13, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke | Behavioral: SCORRE Behavioral: Attention-Control Activity | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 116 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | randomized controlled two-group pre-post test design |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | data collectors conducting post-intervention and 8-week follow up are blinded to participant treatment groups |
Primary Purpose: | Prevention |
Official Title: | Stroke Counseling for Risk Reduction in Young Adult African Americans |
Actual Study Start Date : | March 1, 2017 |
Actual Primary Completion Date : | December 20, 2017 |
Actual Study Completion Date : | December 20, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: SCORRE group
Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
|
Behavioral: SCORRE
3 components based on the Health Belief Model |
Sham Comparator: Attention Control Group
Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
|
Behavioral: Attention-Control Activity
sexual health education |
- Accuracy of perceived stroke risk [ Time Frame: immediately post-intervention ]Comparison of perceived versus actual stroke risk
- Targeted health behaviors [ Time Frame: 8 weeks ]Improvements in targeted health behavior (physical activity, diet, or cigarette smoking)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- self-identify as African American/Black
- age 20-35 years
- able to complete two study visits lasing 1 1/2- 2 hours and a brief daily diary for 8 weeks
- has a cell phone or email address to receive weekly reminders and tips
- has at least one modifiable risk factor for stroke identified during study visit one screening

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03076125
United States, Georgia | |
Georgia State University | |
Atlanta, Georgia, United States, 30294 |
Responsible Party: | Dawn Aycock, Assistant Professor, Georgia State University |
ClinicalTrials.gov Identifier: | NCT03076125 |
Other Study ID Numbers: |
K01NR015494 ( U.S. NIH Grant/Contract ) |
First Posted: | March 10, 2017 Key Record Dates |
Last Update Posted: | December 13, 2018 |
Last Verified: | December 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Primary Stroke Prevention, Risk Factors for Stroke |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |